JP2005502675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005502675A5 JP2005502675A5 JP2003524562A JP2003524562A JP2005502675A5 JP 2005502675 A5 JP2005502675 A5 JP 2005502675A5 JP 2003524562 A JP2003524562 A JP 2003524562A JP 2003524562 A JP2003524562 A JP 2003524562A JP 2005502675 A5 JP2005502675 A5 JP 2005502675A5
- Authority
- JP
- Japan
- Prior art keywords
- mometasone furoate
- formoterol fumarate
- suspension formulation
- metered dose
- dose inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 31
- 229960000193 formoterol fumarate Drugs 0.000 claims 31
- 229960002744 mometasone furoate Drugs 0.000 claims 31
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 31
- 239000000203 mixture Substances 0.000 claims 30
- 238000009472 formulation Methods 0.000 claims 27
- 239000000443 aerosol Substances 0.000 claims 23
- 239000000725 suspension Substances 0.000 claims 23
- 229940071648 metered dose inhaler Drugs 0.000 claims 21
- 238000000034 method Methods 0.000 claims 6
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims 1
- 238000002788 crimping Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002118 epoxides Chemical class 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940063002 magnesium palmitate Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- BJZBHTNKDCBDNQ-UHFFFAOYSA-L magnesium;dodecanoate Chemical compound [Mg+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O BJZBHTNKDCBDNQ-UHFFFAOYSA-L 0.000 claims 1
- ABSWXCXMXIZDSN-UHFFFAOYSA-L magnesium;hexadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O ABSWXCXMXIZDSN-UHFFFAOYSA-L 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31538601P | 2001-08-28 | 2001-08-28 | |
| PCT/US2002/027336 WO2003020253A2 (en) | 2001-08-28 | 2002-08-27 | Pharmaceutical compositions for the treatment of asthma |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009126933A Division JP2009185075A (ja) | 2001-08-28 | 2009-05-26 | 喘息治療用の製薬組成物 |
| JP2010036706A Division JP5170789B2 (ja) | 2001-08-28 | 2010-02-22 | 喘息治療用の製薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005502675A JP2005502675A (ja) | 2005-01-27 |
| JP2005502675A5 true JP2005502675A5 (enExample) | 2006-01-05 |
Family
ID=23224164
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524562A Pending JP2005502675A (ja) | 2001-08-28 | 2002-08-27 | 喘息治療用の製薬組成物 |
| JP2009126933A Pending JP2009185075A (ja) | 2001-08-28 | 2009-05-26 | 喘息治療用の製薬組成物 |
| JP2010036706A Expired - Fee Related JP5170789B2 (ja) | 2001-08-28 | 2010-02-22 | 喘息治療用の製薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009126933A Pending JP2009185075A (ja) | 2001-08-28 | 2009-05-26 | 喘息治療用の製薬組成物 |
| JP2010036706A Expired - Fee Related JP5170789B2 (ja) | 2001-08-28 | 2010-02-22 | 喘息治療用の製薬組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20030114428A1 (enExample) |
| EP (3) | EP1420759B1 (enExample) |
| JP (3) | JP2005502675A (enExample) |
| KR (1) | KR100970531B1 (enExample) |
| CN (2) | CN1649568B (enExample) |
| AR (1) | AR036358A1 (enExample) |
| AT (2) | ATE503461T1 (enExample) |
| AU (1) | AU2002313828B2 (enExample) |
| BR (1) | BR0212089A (enExample) |
| CA (1) | CA2457926A1 (enExample) |
| CO (1) | CO5560551A2 (enExample) |
| CY (2) | CY1109212T1 (enExample) |
| DE (2) | DE60239648D1 (enExample) |
| DK (2) | DK1420759T3 (enExample) |
| ES (3) | ES2361805T3 (enExample) |
| HU (1) | HUP0401514A3 (enExample) |
| MX (1) | MXPA04001875A (enExample) |
| NO (1) | NO20041277L (enExample) |
| NZ (1) | NZ530987A (enExample) |
| PE (1) | PE20030390A1 (enExample) |
| PL (1) | PL209640B1 (enExample) |
| PT (2) | PT2092935E (enExample) |
| SI (2) | SI1420759T1 (enExample) |
| TW (1) | TWI324934B (enExample) |
| WO (1) | WO2003020253A2 (enExample) |
| ZA (1) | ZA200401419B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| EP1785156B1 (en) * | 2002-08-23 | 2012-06-27 | Schering Corporation | Metered dose inhaler containing an aerosol suspension formulation |
| ES2388537T3 (es) * | 2002-08-23 | 2012-10-16 | Merck Sharp & Dohme Corp. | Inhalador dosificador que contiene una formulación en suspensión de aerosol |
| MXPA05002248A (es) * | 2002-08-27 | 2005-06-08 | Schering Corp | Procedimiento para producir formulaciones de inhalador de dosis medida. |
| GB0323685D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| CN1870976A (zh) * | 2003-10-20 | 2006-11-29 | 先灵公司 | 药物组合物 |
| EP1925293A3 (en) * | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| US20050186144A1 (en) * | 2004-01-21 | 2005-08-25 | Schering Corporation | Treatment methods |
| US20110053999A1 (en) | 2004-03-03 | 2011-03-03 | Daley Thomas E | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| DE602005009012D1 (de) * | 2004-10-12 | 2008-09-25 | Generics Uk Ltd | Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| CA2641616A1 (en) * | 2006-02-09 | 2007-08-23 | Schering Corporation | Pharmaceutical formulations |
| BRPI0721256A2 (pt) * | 2007-02-09 | 2013-03-12 | Schering Corp | aerossàis de fÁrmaco farmacÊuticos estÁveis |
| US20080253970A1 (en) * | 2007-02-09 | 2008-10-16 | Schering Corporation | Stable Pharmaceutical Drug Products |
| GB0714239D0 (en) * | 2007-07-20 | 2007-08-29 | Glaxo Group Ltd | Method |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| JP2011509936A (ja) * | 2008-01-10 | 2011-03-31 | シェーリング コーポレイション | 吸入薬物製品、システムおよび使用 |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| EP2414560B1 (de) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Verfahren zur beschichtung einer oberfläche eines bauteils |
| JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PL3111927T3 (pl) * | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| WO2011027247A1 (en) | 2009-09-03 | 2011-03-10 | Sulur Subramaniam Vanangamudi | An antifungal cream comprising terbinafine hydrochloride |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| BR112012012475B1 (pt) | 2009-11-25 | 2020-03-03 | Boehringer Ingelheim International Gmbh | Nebulizador |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| ES2646201T3 (es) * | 2009-12-07 | 2017-12-12 | Horizon Orphan Llc | Formulaciones de 4-metilpirazol |
| WO2011101828A1 (en) | 2010-02-22 | 2011-08-25 | Sulur Subramaniam Vanangamudi | A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it |
| WO2011101830A1 (en) | 2010-02-22 | 2011-08-25 | Sulur Subramaniam Vanangamudi | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it |
| WO2011160932A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012017368A1 (en) | 2010-08-02 | 2012-02-09 | Sulur Subramaniam Vanangamudi | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it |
| WO2012049543A1 (en) | 2010-10-15 | 2012-04-19 | Sulur Subramaniam Vanangamudi | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it |
| EP2694220B1 (de) | 2011-04-01 | 2020-05-06 | Boehringer Ingelheim International GmbH | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| TWI597072B (zh) * | 2011-10-11 | 2017-09-01 | 吉斯藥品公司 | 包覆脂肪酸的β－致效劑之結晶微粒 |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| SG11201507286QA (en) | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
| JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| ES2836977T3 (es) | 2013-08-09 | 2021-06-28 | Boehringer Ingelheim Int | Nebulizador |
| IL247927B (en) | 2014-05-07 | 2022-09-01 | Boehringer Ingelheim Int | Container, a device that turns a liquid into a fine spray and use |
| WO2015169430A1 (en) | 2014-05-07 | 2015-11-12 | Boehringer Ingelheim International Gmbh | Nebulizer |
| CN116036425A (zh) | 2014-05-07 | 2023-05-02 | 勃林格殷格翰国际有限公司 | 喷雾器、指示器装置及容器 |
| EP3160521B1 (en) | 2014-06-30 | 2023-06-07 | Proveris Scientific Corporation | Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods |
| ES2796177T5 (es) | 2015-12-04 | 2024-10-29 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
| GB2545025A (en) * | 2015-12-04 | 2017-06-07 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
| EP3426329A4 (en) | 2016-03-09 | 2019-11-13 | Proveris Scientific Corporation | METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES |
| CN106619658B (zh) * | 2016-12-28 | 2022-02-08 | 四川普锐特药业有限公司 | 一种医用气溶胶制剂及定量吸入气雾剂 |
| WO2021219495A1 (en) | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
| WO2022081847A1 (en) | 2020-10-15 | 2022-04-21 | Proveris Scientific Corporation | Systems and methods for inhaler testing |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| CA2111002C (en) * | 1991-06-10 | 2000-08-22 | Julianne Fassberg | Non-chlorofluorocarbon aerosol formulations |
| US6250300B1 (en) * | 1992-12-11 | 2001-06-26 | Ab Astra | System for dispensing pharmaceutically active compounds |
| EE9700138A (et) * | 1994-12-22 | 1997-12-15 | Astra Aktiebolag | Aerosoolravimvormid |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| CZ294064B6 (cs) * | 1996-08-29 | 2004-09-15 | Schering Corporation | Aerosolový suspenzní přípravek mometazonfuroátu bez chlorfluorovaných uhlovodíků |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US6503537B2 (en) * | 1997-03-20 | 2003-01-07 | Schering Corporation | Preparation of powder agglomerates |
| US6495167B2 (en) * | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| TW533865U (en) * | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| GB2359749B (en) * | 1998-11-26 | 2004-05-05 | Britannia Pharmaceuticals Ltd | Anti-asthmatic combinations comprising surface active phospholipids |
| AR022695A1 (es) * | 1999-01-28 | 2002-09-04 | Schering Corp | PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| SE9900833D0 (sv) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| ATE267582T1 (de) * | 2000-01-20 | 2004-06-15 | Basilea Pharmaceutica Ag | Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen |
| GB0009612D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic formulations |
| AU2001278115A1 (en) * | 2000-08-04 | 2002-02-18 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
| TW200301698A (en) * | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
-
2002
- 2002-08-26 AR ARP020103194A patent/AR036358A1/es not_active Application Discontinuation
- 2002-08-26 TW TW091119250A patent/TWI324934B/zh not_active IP Right Cessation
- 2002-08-27 DK DK02753549T patent/DK1420759T3/da active
- 2002-08-27 CN CN02816685XA patent/CN1649568B/zh not_active Expired - Fee Related
- 2002-08-27 AT AT09006110T patent/ATE503461T1/de active
- 2002-08-27 PT PT09006110T patent/PT2092935E/pt unknown
- 2002-08-27 MX MXPA04001875A patent/MXPA04001875A/es active IP Right Grant
- 2002-08-27 PE PE2002000820A patent/PE20030390A1/es not_active Application Discontinuation
- 2002-08-27 AT AT02753549T patent/ATE430555T1/de active
- 2002-08-27 PT PT02753549T patent/PT1420759E/pt unknown
- 2002-08-27 HU HU0401514A patent/HUP0401514A3/hu unknown
- 2002-08-27 AU AU2002313828A patent/AU2002313828B2/en not_active Ceased
- 2002-08-27 CA CA002457926A patent/CA2457926A1/en not_active Abandoned
- 2002-08-27 EP EP02753549A patent/EP1420759B1/en not_active Expired - Lifetime
- 2002-08-27 EP EP09006110A patent/EP2092935B1/en not_active Expired - Lifetime
- 2002-08-27 DK DK09006110.2T patent/DK2092935T3/da active
- 2002-08-27 CN CN201010156400A patent/CN101856362A/zh active Pending
- 2002-08-27 NZ NZ530987A patent/NZ530987A/en not_active IP Right Cessation
- 2002-08-27 PL PL368897A patent/PL209640B1/pl not_active IP Right Cessation
- 2002-08-27 ES ES09006110T patent/ES2361805T3/es not_active Expired - Lifetime
- 2002-08-27 KR KR1020047002778A patent/KR100970531B1/ko not_active Expired - Fee Related
- 2002-08-27 EP EP10012751A patent/EP2319494B1/en not_active Expired - Lifetime
- 2002-08-27 JP JP2003524562A patent/JP2005502675A/ja active Pending
- 2002-08-27 SI SI200230839T patent/SI1420759T1/sl unknown
- 2002-08-27 DE DE60239648T patent/DE60239648D1/de not_active Expired - Lifetime
- 2002-08-27 ES ES10012751T patent/ES2389480T3/es not_active Expired - Lifetime
- 2002-08-27 SI SI200230943T patent/SI2092935T1/sl unknown
- 2002-08-27 ES ES02753549T patent/ES2325316T3/es not_active Expired - Lifetime
- 2002-08-27 DE DE60232251T patent/DE60232251D1/de not_active Expired - Lifetime
- 2002-08-27 WO PCT/US2002/027336 patent/WO2003020253A2/en not_active Ceased
- 2002-08-27 BR BR0212089-5A patent/BR0212089A/pt not_active IP Right Cessation
- 2002-08-28 US US10/229,855 patent/US20030114428A1/en not_active Abandoned
-
2004
- 2004-02-16 CO CO04012909A patent/CO5560551A2/es not_active Application Discontinuation
- 2004-02-20 ZA ZA2004/01419A patent/ZA200401419B/en unknown
- 2004-03-26 NO NO20041277A patent/NO20041277L/no not_active Application Discontinuation
-
2005
- 2005-03-03 US US11/071,078 patent/US20050147565A1/en not_active Abandoned
-
2009
- 2009-05-26 JP JP2009126933A patent/JP2009185075A/ja active Pending
- 2009-07-08 CY CY20091100723T patent/CY1109212T1/el unknown
- 2009-12-08 US US12/633,510 patent/US20100143269A1/en not_active Abandoned
-
2010
- 2010-02-22 JP JP2010036706A patent/JP5170789B2/ja not_active Expired - Fee Related
-
2011
- 2011-06-28 CY CY20111100617T patent/CY1111726T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502675A5 (enExample) | ||
| JP5170789B2 (ja) | 喘息治療用の製薬組成物 | |
| US5934273A (en) | System for dispensing pharmaceutically active compounds | |
| AU2006278571B2 (en) | Compositions exhibiting improved flowability | |
| TW475904B (en) | Pharmaceutical composition for administration by inhalation and the preparation thereof | |
| US6250300B1 (en) | System for dispensing pharmaceutically active compounds | |
| EP2309978B1 (en) | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof | |
| CZ20013185A3 (cs) | Farmaceutický prostředek | |
| JPS63502895A (ja) | 新規な吸入用製薬組成物 | |
| EP1296663A2 (en) | Highly efficient delivery of a large therapeutic mass aerosol | |
| JP4348179B2 (ja) | 安定な粉末吸入投与組成物 | |
| CN116615201A (zh) | 丙酸氟替卡松和硫酸沙丁胺醇的可吸入制剂 | |
| CN102458372A (zh) | 适用在干粉吸入器中的聚结物制剂 | |
| JP2006312649A (ja) | 薬学的組成物 | |
| CN116077471A (zh) | 一种供吸入用的粉雾剂组合物及其制备方法和应用 | |
| Vanderbist et al. | Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent | |
| JP2025526811A (ja) | 吸入可能なエピネフリン製剤 | |
| CA2575957C (en) | Process for preparing a medicament | |
| JP5345605B2 (ja) | 乾燥粉末吸入組成物の製造方法 | |
| WO2022045995A1 (en) | A process for the preparation of dry powder compositions for inhalation | |
| CA2456721C (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| WO2019098969A2 (en) | Dry powder compositions for inhalation | |
| TWI383807B (zh) | 醫學氣霧配方 | |
| JP2002161030A (ja) | 異なる粒径をもった混合粉体の吸入方法 | |
| WO2022146255A1 (en) | A process for the preparation of dry powder compositions for inhalation |